In the latest trading session,, 0.56 million BioNTech SE ADR (NASDAQ:BNTX) shares changed hands as the company’s beta touched 1.35. With the company’s most recent per share price at $105.71 changing hands around $3.69 or 3.61% at last look, the market valuation stands at $25.37B. BNTX’s current price is a discount, trading about -24.39% off its 52-week high of $131.49. The share price had its 52-week low at $76.53, which suggests the last value was 27.6% up since then. When we look at BioNTech SE ADR’s average trading volume, we note the 10-day average is 1.82 million shares, with the 3-month average coming to 1.03 million.
Analysts gave the BioNTech SE ADR (BNTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 2 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended BNTX as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. BioNTech SE ADR’s EPS for the current quarter is expected to be -2.35.
BioNTech SE ADR (NASDAQ:BNTX) trade information
Instantly BNTX is in green as seen in intraday trades today. With action 3.83%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -7.24%, with the 5-day performance at 3.83% in the green. However, in the 30-day time frame, BioNTech SE ADR (NASDAQ:BNTX) is 10.80% up. Looking at the short shares, we see there were 4.34 million shares sold at short interest cover period of 4.17 days.
The consensus price target for the stock as assigned by Wall Street analysts is 126, meaning bulls need an upside of 16.1% from its recent market value. According to analyst projections, BNTX’s forecast low is 121 with 145 as the target high. To hit the forecast high, the stock’s price needs a -37.17% plunge from its current level, while the stock would need to soar -14.46% for it to hit the projected low.
BioNTech SE ADR (BNTX) estimates and forecasts
Year-over-year growth is forecast to reach -23.14% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 161.67M. 10 analysts are of the opinion that BioNTech SE ADR’s revenue for the current quarter will be 131.45M. The company’s revenue for the corresponding quarters a year ago was 187.6M and 128.7M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -13.82%. The estimates for the next quarter sales put growth at 2.14%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -25.87%. The 2025 estimates are for BioNTech SE ADR earnings to decrease by -91.42%, but the outlook for the next 5-year period is at -17.77% per year.
BNTX Dividends
BioNTech SE ADR is expected to release its next quarterly earnings report on 2025-Mar-09.
BioNTech SE ADR (NASDAQ:BNTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 63.23% of BioNTech SE ADR shares while 21.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 59.46%. There are 21.87% institutions holding the BioNTech SE ADR stock share, with BAILLIE GIFFORD & CO the top institutional holder. As of 2024-06-30, the company held 3.4425% of the shares, roughly 8.28 million BNTX shares worth $665.08 million.
PRIMECAP MANAGEMENT CO/CA/ holds the second largest percentage of outstanding shares, with 1.9922% or 4.79 million shares worth $384.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund and PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund . With 2.27 shares estimated at $240.19 million under it, the former controlled 0.95% of total outstanding shares. On the other hand, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund held about 0.47% of the shares, roughly 1.12 shares worth around $118.41 million.
